PMPRB Update Pharma Symposium Canada March 31, 2015.

Slides:



Advertisements
Similar presentations
Pharmaceutical Policy and Pricing: How are Countries Getting Greater Value? Commonwealth Fund/ Alliance for Health Reform Briefing on Capitol Hill Dr.
Advertisements

Pricing and paying for medicines Ad Antonisse AstraZeneca BV April 2005.
Pharmacare 2020 Conference Vancouver, Feb 26-27, 2013 Michelle Boudreau Executive Director, PMPRB.
Canada’s Patented Medicine Prices Review Board
November 26, Fall Forum Alberta’s Pharmaceutical Strategy and Programs Policy Recommendations.
Pricing and Reimbursement Policies 27. Pricing Policies Patented Medicines Patented Medicine Prices Review Board (PMPRB) monitors and sets the price of.
Controlling Drug Prices: What Canada Does Joel Lexchin MD School of Health Policy & Management York University.
Portugal Economic Evaluation Applied to Decision Making Isaura Vieira INFARMED, I.P. – National Authority for Medicines and Health Products I Pan-American.
R e l e a s e d: m a r c h 3 1, Cost-drivers of public drug plans in canada E l e n a l u n g u Manager, NPDUIS, PMPRB 2015 CADTH Symposium.
The evolving role of real-world evidence to support policy and practice CADTH 2015.
SEBs – A Public Payer Perspective
Service Integration The Canadian Way Presentation to the King’s Fund Study Tour September 17 th, 2007 Cathy Fooks President and CEO The Change Foundation.
Background Pharmacy and Therapeutics Committees function at various levels to make formulary decisions Independent process resulting in variations in.
1 The Budget Impact of Drugs Treating Rare Diseases in Canada: A MIDAS Sales Data Analysis April 14, 2015 Oral Presentation at the 2015 CADTH.
The Global Generic Medications Market
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Canadian Generic Pharmaceutical Association Getting to the Heart of Drug Sustainability – The Issues Canada’s Public Policy Forum - Atlantic Summit On.
Major Health Issues The Affordable Healthcare Act.
The Pharmaceutical Industry in Europe Key data INDUSTRY (EFPIA Total) (*) Production63,127121,311158,647170,000 (e) Exports23,18089,443144,022170,000.
Price Regulation of Patented Medicines in Canada
Healthcare Reform in China and Its Impact on the Pharmaceutical Industry Hengpeng Zhu Institute of Economics Chinese Academy of Social Sciences
A Presentation of the Colorado Health Institute 303 E. 17 th Avenue, Suite 930 Denver, Colorado (Twitter)
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Applying the Federal Cabinet Directive on Streamlining Regulation Regulatory Craft in Nova Scotia Conference 2007 Halifax, Nova Scotia November 20, 2007.
Michelle Boudreau, Vice President, Private Markets, March 11, 2015 Presentation to CADA.
Michelle Boudreau, Executive Director 4 th Annual Market Access Summit November 21, 2012 Toronto Patented Medicines Prices Review Board (PMPRB): Regulatory.
Michelle Boudreau, Executive Director Ottawa Convention Centre September 25, 2012 Patented Medicines Prices Review Board (PMPRB) to Canadian Association.
Michelle Boudreau, Executive Director Pricing and Reimbursement Toronto, Ontario June 11, 2012 Patented Medicines Prices Review Board (PMPRB): 25 Years.
Maryland's New Demonstration Waiver Michael B. Robbins, Senior Vice President April 28, 2015.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Subsequent Entry Biologics (SEBs) – Canada Presentation to AIPLA Biotechnology Committee January 25, 2012 Daphne C. Lainson
Healthcare Reform Update HAMA Fall Meeting October 6, 2010.
Benchmarking Canadian HTA Agency and Provincial Payer Decision-Making Allen N. 1,2, Liberti L. 2, Salek M.S. 1 1 Centre for socioeconomic research, School.
Pharmaceutical Marketing Club of Quebec Russell Williams President Canada’s Research-Based Pharmaceutical Companies (Rx&D)
Universal Pharmacare: Solving Canada’s Drug Problem Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition.
The Pharmaceutical Industry in Turkey
Drug Prices in Canada and the US: More Than Meets the Eye? National Academy of Social Insurance Annual Conference Wayne Critchley Executive Director, PMPRB.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Competitiveness of the European-based Pharmaceutical Industry Prospective of a New Member State Imre Hollo Deputy Secretary of State, MOH Hungary.
Reforming Health Care: Making Sense of Health Care Finance amid Growing Underinsurance Leonard Rodberg, PhD Urban Studies Dept., Queens College/CUNY Prepared.
Title text here Consumer Perspective on Containing Drug Costs Leigh Purvis, Director, Health Services Research.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
THE COMMONWEALTH FUND Figure 1. Medicare’s Success in Achieving Major Goals “How successful has Medicare been in accomplishing each of the following specific.
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
Country Presentations Canada. Canada’s Pharmaceutical DNA and Key Challenges and Opportunities.
Douglas Clark Executive Director PMPRB
The Use of the World Health Organization’s Defined Daily Dose in Drug Cost & Utilization Analyses Elena Lungu Senior Economist 2008 CADTH Symposium Edmonton,
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015 Average annual growth rate of prescription drug spending per capita.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Drug Formulary Development & Management
Connecticut Pharmaceutical Forum: Access, Affordability, and Better Health Tara C. F. Ryan May 17, 2016.
Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.
Peterson-Kaiser Health System Tracker What are the recent and forecasted trends in prescription drug spending?
Continuous Improvement & Real World Evidence: A Public Payer’s Perspective Suzanne McGurn, Assistant Deputy Minister and Executive Officer Ontario Public.
iHEA 9th World Congress Sydney, July 8, 2013
Economics of Pharmaceutical Regulation in the Mediterranean: the case of Spain and Italy Joan Costa Font LSE.
Douglas Clark Executive Director PMPRB
Free Trade and Intellectual Property Rights: Implications for the Canadian Pharmaceutical Environment Joel Lexchin MD School of Health Policy & Management.
The U.S. Health Care System: An International Perspective
National Pharmacare in Canada: Choosing a Path Forward
An Increasing Demand for Prescription Drugs Drives Profitability
Prescription for Pharmaceutical Reform: Healing an Ailing System
CADTH Overview Barb Shea, Vice-President, COMPUS
COMPUS Overview Denis Bélanger Heather Bennett Steve Graham
Germany’s Approach to Prescription Drug Pricing
Pharmacy – Fully Insured versus Self Funding
Germany’s Approach to Prescription Drug Pricing
Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.
Presentation transcript:

PMPRB Update Pharma Symposium Canada March 31, 2015

Canadian pricing and reimbursement regime Canada is the only developed country in the world with a universal public health insurance program that excludes coverage for prescription drugs. As such, Canada is fairly unique in that it does not have a national pharmaceutical negotiator and formulary for its population. Federally, the PMPRB reviews patented drugs and sets price ceilings based on level of therapeutic improvement, domestic prices and prices in the “PMPRB7”.* At the provincial level, CADTH reviews drugs for therapeutic benefit and cost effectiveness and makes reimbursement recommendations to participating public payers.

Pricing and reimbursement (continued) Provincial and territorial health ministries negotiate prices directly with manufacturers, either individually or under the auspices of the pCPA. Private insurers manage employer-sponsored drug plans and also negotiate prices with manufacturers, but wield less purchasing power than provinces. Uninsured Canadians (mainly the working poor) pay for prescription drugs at “list” prices. One in ten Canadians said to be unable to afford to fill their prescriptions (CMAJ 2012). Payer Share of drug costs Public insurance 42% Private insurance 35% Out-of-pocket (uninsured) 23%

Pharmaceutical Regulation in Canada is Shared PMPRB Jurisdiction covers patented drug products sold in Canada, whether through market approval or under Health Canada’s Special Access Program (SAP) Over Life of Patent(s) Health Canada Review For Safety, Efficacy & Quality Health Canada Post-Market Surveillance Market Approval Private Drug Plan Reimbursement Public Drug Plan Reimbursement CADTH Common Drug Review Individual Federal/Provincial Public Drug Plan Listing

Drug share of total health spending (2012) Drugs are the second/third (depending on year) largest health cost for Canada, but they are by far the largest health cost for uninsured Canadians .

PMPRB 101 The PMPRB is an independent, quasi-judicial consumer protection agency with a regulatory and reporting mandate. We are 60 civil servants on “staff” and 5 Cabinet-appointed Board members. On the regulatory side, staff review patented drug prices to ensure they are not excessive as per the Patent Act and corresponding Regulations and Guidelines. Where staff considers the price of a drug to be excessive, a patentee can agree to pay back excess revenues and/or lower its price through a voluntary settlement (VCU). If the patentee refuses a VCU, a hearing will be held before a panel of Board members if the Chairperson considers it in the public interest. If the panel decides a drug is excessively priced, it can order the patentee to reduce its price and/or pay back excess revenues.

Regulatory mandate At intro, a drug’s price ceiling is set based on its category of therapeutic improvement, the price of domestic comparators and its price elsewhere in the PMPRB7.* Four therapeutic categories, with descending price ceilings (in theory): Breakthrough Substantial Improvement Moderate Improvement Slight/No Improvement After introduction, an existing drug is eligible for CPI-based price increases. At no time can a drug’s price exceed the highest in the PMPRB7 (HIPC rule). * France, Germany, Italy, Sweden, Switzerland, the UK and the US.

Reporting mandate Annual Report Analysis of prices of patented drugs, price trends of all drugs, and R&D spending: http://www.pmprb-cepmb.gc.ca/en/reporting/annual-reports National Prescription Drug Utilization Information System (NPDUIS) Established in 2001 as an F/P/T research initiative to provide policy makers and drug plan managers with analyses of price, utilization and cost trends The NPDUIS Advisory Committee advises the PMPRB and provides expert oversight and guidance for the analytical reporting of the initiative The Committee is composed of BC, AB, SK, MB, ON, NB, NS, PEI, NL, YK, NIHB & HC, CIHI and CADTH.

NPDUIS Reports published in 2014/15 CompassRx, 2012-13 Generic Drugs in Canada, 2013 – December 11, 2014 New Drug Pipeline Monitor, 6th edition – December 2013 Utilization of Prescription Opioids in Canada's Public Drug Plans, 2006/07 to 2012/13 – April 2014 Research agenda Private Drug Plans in Canada: Generic Drug Market, 2013 International Retail Price Comparison, 2013 Compass Rx, 2013-14 Private Drug Plans in Canada: Cost Driver Analysis, 2013 Utilization and Cost of Biologics, 2005/06 to 2012/13 Private Drug Plans in Canada: High-Cost Drugs, 2013 New Drug Launch Monitor, 2014 New Drug Pipeline Monitor, 7th edition

New NPDUIS flagship report Comprehensive analysis of cost drivers in public drug plans: Price effects Demographic effects Volume effects Drug-mix effects Release date is today! http://www.pmprb-cepmb.gc.ca/

Compass Rx – “push-pull” drug spending effect Although net growth in drug spending has been low in recent years because of the “pull effect” of increased generic substitution and generic price reductions, that phenomenon appears to have run its course. In the coming years, the cost drivers behind the “push effect” are expected to pose a challenge to the sustainability of both public and private drug plans, for example, in 2014: Spending on high cost biologics grew by 10.4%; Spending on high cost oncology drugs grew by 12.3%. Total Push Effects 8.5% Demographic Volume Drug-Mix Price change Generic Subs Total Pull Effects -9.2%

Has Canada already turned the corner? Source: IMS Brogan. Canadian Drug Stores and Hospitals Purchases, MAT December 2014

Latest data on drug-mix effect Source: IMS Brogan. Canadian Drug Stores and Hospitals Purchases, MAT December 2014

Canada’s performance is not strong within PMPRB7… Source: IMS MIDAS, 2013

… nor within the OECD OECD Average: $498 Source: OECD, 2012

… and price is clearly a contributing factor

Why are prices going down in other countries? Over the 2010-2012 period, 23 European countries began planning or executed a major reform of their pharmaceutical price regulatory framework. Country Year Type of Reform UK 2014 Annual, per company, public expenditure ceilings – 0% growth for next two years. Sweden 7.5% price reduction for drugs >15 years old not subject to generic competition. Switz 2013 Legislated negotiated price reduction of 2500 drugs. Italy Expenditure ceiling, performance based reimbursement, 2-year price re-evaluation. France 2012 Mandatory price review every 5 years, reimbursement rates cut for low innovation medicines, new stringent therapeutic evaluations. Germany 2011 Consolidation of regulatory roles, mandatory rebates to public plans.

Germany: impact of AMNOG Canada 2011 “AMNOG” reform is expected to save €2 billion per year and has already reduced the price of the 25 top-selling brand drugs by an average of 23%.

As prices go up, R&D is going down

Why is this happening? R&D Evidence does not support purported link between price, IP and R&D. Other factors, such as head office location, science base, clinical trial infrastructure, population density, etc. appear to be better predictors of locus of pharmaceutical R&D Price As noted, EU countries are taking aggressive action to control drug costs. No national purchasing authority in Canada, and key decisions impacting price are made independently of one another by different F/P/T players. PMPRB regime not keeping up with international or industrial trends.

Payers are concerned about sustainability “The (provincial drug plan) programs are starting to face extreme financial constraints. The growth that we’re seeing in some categories of drugs is far beyond what were ever anticipated four or five years ago.” Fred Horne, Alberta Minister of Health, speaking at April 7, 2014 CADTH symposium “We’re now at a point where ongoing sustainability of meaningful prescription drug coverage is threatened for a vast number of Canadians. In the past few years alone, the number of very-high-cost medications for genetic disorders, cancer and auto-immune diseases has increased substantially -- and this trend is expected to continue. Frank Swedlove, President of CLHIA, speaking at the October 30, 2013 Conference Board 2nd Summit on Sustainable Health Care

What’s next for the PMPRB? In 1987, Canada signalled its willingness to pay its “fair share” of international drug development costs with enactment of present day drug patent policy – Bill C-22. Bill C-22 also created PMPRB as consumer protection “pillar” of that policy. PMPRB7 selected on basis of assumption that by offering comparable “fair” prices and patent rights, Canada would come to “emulate” R&D levels in these countries. With Canadian prices approaching second highest of PMPRB7 and R&D at record lows, that assumption now being questioned, as is relevance of PMPRB. Timing opportune for fresh look at PMPRB framework in light of current CETA changes, sustainability concerns and GoC priorities (eg. price gap, defending consumers). PMPRB to publish new three year strategic plan in spring 2015 – stay tuned…

Twitter: @PMPRB_CEPMB Thank you. Merci. www.pmprb-cepmb.gc.ca Twitter: @PMPRB_CEPMB 23